Suzhou Meichuang Medical Technology Co., Ltd. has recently announced the successful completion of equity financing totaling hundreds of millions of yuan. This round of funding was jointly contributed by prominent investors such as Su Venture Capital, Heaven Silicon Valley, Guanghua Wutong, and Medpark, with Kaicheng Capital once again serving as the exclusive financial advisor. This marks the second time within six months that Meichuang Medical has garnered the support of esteemed capital providers, following an investment of over 100 million yuan earlier in 2025. To date, the company has raised a cumulative financing amount exceeding 200 million yuan.

Meichuang Medical specializes in the research and development of peripheral vascular and tumor interventional products. A significant milestone for the company is the successful mass production of medical implant-grade ePTFE materials, positioning it as the first domestic enterprise to master this advanced technology. The proceeds from this latest financing round will be allocated towards accelerating the commercialization and global expansion of Meichuang Medical's products.